Boehringer–Minapharm: rec protein production technology, 2011– collab Boehringer early adopter of ProBioGen’s GlymaxX afucosylation technology

	Period	2011-01-01
	Partner, 1st	Boehringer Ingelheim (Group)
	Partner, 2nd	ProBioGen AG
	Group	Minapharm (Group)
	Product	GlymaxX® technology
	Product 2	biopharmaceutical production technology (biomanufacturing)

ProBioGen AG. (1/10/23). "Press Release: ProBioGen Collaborates with Boehringer Ingelheim on DirectedLuck Transposase Technology". Berlin.

ProBioGen announced today a new non-exclusive collaboration with Boehringer Ingelheim on ProBioGen's DirectedLuck® transposase technology.

ProBioGen and Boehringer Ingelheim have a long legacy of fruitful collaboration going back to 2011, when the company was one of the early adopters of ProBioGen's afucosylation technology GlymaxX®. The collaboration around the ProBioGen DirectedLuck transposase technology, thus, marks an exciting continuation of the two companies' legacy.

The new project further expands the partner's long-term collaboration on new technologies for R&D. It contributes to Boehringer Ingelheim's goal of using cutting-edge technologies across the whole biopharmaceutical value chain to achieve its goal of accelerating the development of novel treatments and transforming the lives of millions of humans and animals.

Financial terms of the agreement were not disclosed.

About DirectedLuck

ProBioGen's DirectedLuck transposase system combines an optimized highly active transposase and transposon with epigenetic targeting. It is equipped with a recognition domain for specific histone marks that integrates multiple copies of transgene expression units individually at genomic regions with highest transcriptional activity. As a result, it achieves exceptionally high protein expression and maximum stability in clone pools and clones. This reduces time and manual lab work for selecting superior clones for best titers, proven stability and product quality.

The DirectedLuck Transposase is compatible with genetic elements in standard expression vector design and can be used with host cell lines of different species and tissue origin. DirectedLuck delivers superior cell lines for standard mAbs and complex glycoproteins and provides additional benefits for bispecifics and virus producer cell lines where it allows gradual adjustment of relative expression levels for optimal product quality.

DirectedLuck is available for out-licensing. Furthermore, ProBioGen applies DirectedLuck as a standard tool in clients' service projects at no extra charge.

About ProBioGen

ProBioGen is a Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins.

Combining both state-of-the-art development services, based on ProBioGen's CHO.RiGHT® expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties. Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).

ProBioGen has been operational for more than 25 years. At three locations in Berlin, nearly 300 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisition. Diversification is a complement driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow.

For more information about ProBioGen, follow us on LinkedIn.

ProBioGen Contact:

Dr. Gabriele Schneider
Chief Business Officer
[email protected]

Press Contact:

Sarah Wandrey
Corporate Communications
[email protected]